Analyst firms · Oppenheimer · ORIC
Oppenheimer ORIC price target and rating history
Oric Pharmaceuticals Inc. (ORIC) · Health Care
Oppenheimer rates Oric Pharmaceuticals Inc. (ORIC) Outperform with a $14 price target, as of its latest action on Mar 16, 2023. It has published 3 rating actions on ORIC since March 2022, including 1 upgrade and 1 downgrade. Across 6 firms with a ORIC price target in the last 12 months, the median target is $23.50.
- Current rating
- Outperform
- Price target
- $14
- Median target, all firms
- $23.50
- Actions on ORIC
- 3
Every Oppenheimer rating on ORIC
- Mar 16, 2023
- Jul 18, 2022
- Mar 22, 2022
How other firms rate ORIC
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Leerink Partners | Outperform | $26 | Oct 5, 2026 |
| BTIG | Buy | $26 | Sep 23, 2026 |
| Stifel | Buy | $14 | Jun 12, 2026 |
| Goldman Sachs | Buy | $15 | May 15, 2026 |
| Piper Sandler | Overweight | $22 | Jan 7, 2026 |
| Evercore ISI | Outperform | $25 | Nov 20, 2025 |
| Wolfe Research | Peer Perform | Nov 18, 2025 |
Questions about Oppenheimer and ORIC
- What is Oppenheimer's price target for ORIC?
- Oppenheimer's latest stated price target for Oric Pharmaceuticals Inc. (ORIC) is $14, from its action on Mar 16, 2023.
- What is Oppenheimer's rating on ORIC?
- Oppenheimer rates ORIC Outperform, a bullish rating, as of Mar 16, 2023.
- When did Oppenheimer last change its view on ORIC?
- On Mar 16, 2023, Oppenheimer upgrades to Outperform from Perform, price target $14.
- How does Oppenheimer's ORIC target compare with other analysts?
- Across 6 firms with a ORIC price target in the last 12 months, the median target is $23.50.
More ORIC rating histories
All Oppenheimer ratingsORIC news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.